º¥Á¶µð¾ÆÁ¦ÇÉ°è ¾àÁ¦ ½ÃÀå : Á¦Ç°º°, Åõ¿© °æ·Îº°, ¿ëµµº°, À¯Åë ä³Îº°, Áö¿ªº°
Benzodiazepine Drugs Market, By Product, By Route of Administration, By Application, By Distribution Channel, By Geography
»óǰÄÚµå : 1672706
¸®¼­Ä¡»ç : Coherent Market Insights
¹ßÇàÀÏ : 2025³â 02¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹®
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,500 £Ü 6,511,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 7,000 £Ü 10,128,000
PDF (Multi User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 7¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 10,000 £Ü 14,469,000
PDF (Enterprise User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¼¼°èÀÇ º¥Á¶µð¾ÆÁ¦ÇÉ°è ¾àÁ¦ ½ÃÀåÀº 2025³â¿¡´Â 33¾ï 5,680¸¸ ´Þ·¯¸¦ ±â·ÏÇÒ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù. 2032³â¿¡´Â 44¾ï 2,030¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ°í, 2025-2032³â¿¡ °ÉÃÄ CAGR 4.0%¸¦ ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

º¸°í ¹üÀ§ º¸°í¼­ ¼¼ºÎÁ¤º¸
±âÁØ ¿¬µµ 2024³â 2025³â ½ÃÀå ±Ô¸ð 33¾ï 5,680¸¸ ´Þ·¯
½ÇÀû µ¥ÀÌÅÍ 2020-2024³â ¿¹Ãø ±â°£ 2025-2032³â
¿¹Ãø ±â°£(2025-2032³â) CAGR 4.00% 2032³â ±Ý¾× ¿¹Ãø 44¾ï 2,030¸¸ ´Þ·¯
±×¸². º¥Á¶µð¾ÆÁ¦ÇÉ°è ¾àÁ¦ ½ÃÀå Á¡À¯À²(%), 2025³â, Áö¿ªº°
Benzodiazepine Drugs Market-IMG1

¼¼°èÀÇ º¥Á¶µð¾ÆÁ¦ÇÉ°è ¾àÁ¦ ½ÃÀåÀº ÁÖ¿ä ±¹°¡¿¡¼­ ºÒ¾È Àå¾Ö¿Í ¼ö¸éÀå¾ÖÀÇ À¯º´·ü »ó½ÂÀ¸·Î ÇöÀúÇÑ ¼ºÀåÀ» ÀÌ·ç°í ÀÖ½À´Ï´Ù. º¥Á¶µð¾ÆÁ¦ÇÉÀº ÁßÃ߽Űæ°è¿¡ ÀÛ¿ëÇÏ¿© ºÒ¸éÁõ, ºÒ¾È, ÃÊÁ¶, ¹ßÀÛ, °øÈ² ¹ßÀÛ, ±ÙÀ° °æ·Ã µîÀÇ Áõ»óÀ» Ä¡·áÇϱâ À§ÇØ Ã³¹æµÇ´Â ÇâÁ¤½Å¼ºÀǾàǰÀÇ ÀÏÁ¾À¸·Î, ºÒ¸éÁõ, ºÒ¾È, ÃÊÁ¶, ¹ßÀÛ, °øÈ² ¹ßÀÛ, ±ÙÀ° °æ·Ã µîÀÇ Áõ»óÀ» Ä¡·áÇÏ´Â µ¥ »ç¿ëµË´Ï´Ù. À̵éÀº ÁßÃß ½Å°æ ¾ïÁ¦Á¦·Î ÀÛ¿ëÇÏ¿© ³úÀÇ ºñÁ¤»óÀûÀÎ ÈïºÐÀ» ¾ïÁ¦ÇÏ´Â ÇÑÆí ÁøÁ¤À» À¯µµÇÕ´Ï´Ù. º¥Á¶µð¾ÆÁ¦ÇÉ°è ¾àÁ¦´Â ¼ö¸é, ºÒ¾È, ±ÙÀ°ÀÇ ±äÀåÀ» Á¶ÀýÇÏ´Â GABAA ¼ö¿ëüÀÇ ÀÛ¿ëÀ» ÁõÁø½Ãŵ´Ï´Ù. ¶ÇÇÑ º¥Á¶µð¾ÆÁ¦ÇÉÀº ¾ËÄÚ¿Ã ÀÌÅ» Áõ»óÀÇ ¿ÏÈ­¿Í ÇÔ²² ºÒ¾È Àå¾Ö¿Í ¼ö¸éÀå¾ÖÀÇ ´Ü±â °ü¸®¿¡ ³Î¸® ¹èÇյǾî ÀÖ½À´Ï´Ù.

½ÃÀå ¿ªÇÐ

¶óÀÌÇÁ ½ºÅ¸ÀÏÀÇ º¯È­¿Í ½ºÆ®·¹½º ¼öÁØ Áõ°¡·Î Àü¹ÝÀûÀÎ ºÒ¾È Àå¾Ö¿Í ºÒ¸éÁõ°ú °°Àº Áõ»óÀÇ À¯º´·üÀÌ ³ô¾ÆÁö°í ÀÖÀ¸¸ç, º¥Á¶µð¾ÆÁ¦ÇÉ°è ¾àÁ¦ ¼ö¿ä°¡ ¼¼°èÀûÀ¸·Î ³ô¾ÆÁú °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. WHO°¡ ¹ßÇ¥ÇÑ º¸°í¼­¿¡ µû¸£¸é ¼¼°è ¾à 2¾ï 6,400¸¸ ¸íÀÌ ¿ì¿ïÁõ°ú ºÒ¾È ½Å°æÁõÀ» ¾Î°í ÀÖ½À´Ï´Ù. ¹Ì±¹ ºÒ¾È¡¤¿ì¿ïÁõ Çùȸ¿¡ µû¸£¸é ¹Ì±¹ÀÎÀÇ 38% ÀÌ»óÀÌ ºÒ¾È Áõ»óÀ» °æÇèÇϰí ÀÖ½À´Ï´Ù. Á¤½Å °Ç°­ ¹®Á¦ÀÇ Áõ»óÀ» °ü¸®Çϱâ À§ÇØ º¥Á¶µð¾ÆÁ¦ÇÉ°è ¾àÁ¦ÀÇ Ã¤¿ëÀÌ Áõ°¡ÇÏ´Â °ÍÀº ¼¼°èÀÇ º¥Á¶µð¾ÆÁ¦ÇÉ°è ¾àÁ¦ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ ¼ö ÀÖ½À´Ï´Ù. ±×·¯³ª, Á¹À½, Çö±âÁõ, ÇùÁ¶¼º ¹× ±â¾ï·ÂÀÇ ÀúÇÏ µî, º¥Á¶µð¾ÆÁ¦ÇÉ°è ¾àÁ¦ÀÇ Àå±â »ç¿ë¿¡ ¼ö¹ÝÇÏ´Â ºÎÀÛ¿ë¿¡ °üÇÑ ¿ì·Á µîÀÇ ¿äÀÎÀº ½ÃÀå °ü°èÀÚ¿¡°Ô À־ °úÁ¦°¡ µÉ ¼ö ÀÖ½À´Ï´Ù. °Ô´Ù°¡, ´ëü Ä¡·á°¡ À̿밡´ÉÇÏ´Ù´Â °ÍÀº ¿¹Ãø ±â°£ µ¿¾È ½ÃÀå ¼ºÀåÀ» ¹æÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ÇÑÆí, ºÎÀÛ¿ëÀÌ ÀûÀº º¸´Ù ¾ÈÀüÇÑ º¥Á¶µð¾ÆÁ¦ÇÉ°è ¾àÁ¦ÀÇ °³¹ßÀ» ÁøÇàÇÏ´Â °ÍÀº °¡±î¿î ¹Ì·¡ ½ÃÀå ¼ºÀå¿¡ À־ Å« ±âȸ°¡ µË´Ï´Ù.

º» Á¶»çÀÇ ÁÖ¿ä Æ¯Â¡

¸ñÂ÷

Á¦1Àå Á¶»çÀÇ ¸ñÀû°ú ÀüÁ¦Á¶°Ç

Á¦2Àå ½ÃÀå Àü¸Á

Á¦3Àå ½ÃÀå ¿ªÇÐ, ±ÔÁ¦, µ¿Ç⠺м®

Á¦4Àå ¼¼°èÀÇ º¥Á¶µð¾ÆÁ¦ÇÉ°è ¾àÁ¦ ½ÃÀå - Äڷγª¹ÙÀÌ·¯½º(COVID-19) ÆÒµ¥¹ÍÀÇ ¿µÇâ

Á¦5Àå ¼¼°èÀÇ º¥Á¶µð¾ÆÁ¦ÇÉ°è ¾àÁ¦ ½ÃÀå, Á¦Ç°º°(2020-2032³â), 100¸¸ ´Þ·¯

Á¦6Àå ¼¼°èÀÇ º¥Á¶µð¾ÆÁ¦ÇÉ°è ¾àÁ¦ ½ÃÀå, Åõ¿© °æ·Îº°(2020-2032³â), 100¸¸ ´Þ·¯

Á¦7Àå ¼¼°èÀÇ º¥Á¶µð¾ÆÁ¦ÇÉ°è ¾àÁ¦ ½ÃÀå, ¿ëµµº°(2020-2032³â), 100¸¸ ´Þ·¯

Á¦8Àå ¼¼°èÀÇ º¥Á¶µð¾ÆÁ¦ÇÉ°è ¾àÁ¦ ½ÃÀå, À¯Åë ä³Îº°(2020-2032³â), 100¸¸ ´Þ·¯

Á¦9Àå ¼¼°èÀÇ º¥Á¶µð¾ÆÁ¦ÇÉ°è ¾àÁ¦ ½ÃÀå, Áö¿ªº°(2020-2032³â), 100¸¸ ´Þ·¯

  • ¾ÆÇÁ¸®Ä«
      • ºÏ¾ÆÇÁ¸®Ä«
      • Áß¾Ó¾ÆÇÁ¸®Ä«
      • ³²¾ÆÇÁ¸®Ä«

    Á¦10Àå °æÀï ±¸µµ

    • ±â¾÷ ÇÁ·ÎÆÄÀÏ
      • Torrent Pharmaceuticals Ltd.
      • Mallinckrodt Pharmaceuticals
      • Pfizer Inc.
      • Viatris(Mylan NV)
      • Labiana Pharmaceuticals
      • Bausch Health Companies, Inc.
      • Teva Pharmaceutical Industries Ltd.
      • Amneal Pharmaceuticals LLC
      • Sun Pharmaceutical Industries Ltd.
      • Aurobindo Pharma
      • Par Pharmaceutical
      • Intas Pharmaceuticals Ltd.
      • Neurelis, Inc.
      • Almatica Pharma LLC
      • Esteive Therapeutics, Inc.
      • F.Hoffmann-La Roche Ltd.
      • Wockhardt UK Ltd
      • Lupin
      • Hikma Pharmaceuticals PLC

    Á¦11Àå ¾Ö³Î¸®½ºÆ® Ãßõ

    • À¶¼º°ú ¼èÅð
    • ÀϰüÇü ±âȸ ¸Ê

    Á¦12Àå Âü°í¹®Çå°ú Á¶»ç¹æ¹ý

    • Âü°í¹®Çå
    • Á¶»ç¹æ¹ý
    KTH
  • ¿µ¹® ¸ñÂ÷

    ¿µ¹®¸ñÂ÷

    Global Benzodiazepine Drugs Market is estimated to be valued at USD 3,356.8 Mn in 2025 and is expected to reach USD 4,420.3 Mn by 2032, growing at a compound annual growth rate (CAGR) of 4.0% from 2025 to 2032.

    Report Coverage Report Details
    Base Year: 2024 Market Size in 2025: USD 3,356.8 Mn
    Historical Data for: 2020 To 2024 Forecast Period: 2025 To 2032
    Forecast Period 2025 to 2032 CAGR: 4.00% 2032 Value Projection: USD 4,420.3 Mn
    Figure. Benzodiazepine Drugs Market Share (%), By Region 2025
    Benzodiazepine Drugs Market - IMG1

    Global benzodiazepine drugs market has been witnessing significant growth due to rising prevalence of anxiety and sleep disorders across major countries. Benzodiazepines are a class of psychoactive drugs that are prescribed to treat conditions such as insomnia, anxiety, agitation, seizures, panic attacks and muscle spasms by their effect on the central nervous system. These act as central nervous system depressants, reducing abnormal excitement in the brain, while inducing sedation. Benzodiazepines enhance the effect of the GABAA receptors, which are responsible to regulating aspects of sleep, anxiety and muscle tension. Moreover, benzodiazepines are widely prescribed for short term management of anxiety and sleep disorders along with symptomatic relief of alcohol withdrawal.

    Market Dynamics:

    Growing prevalence of conditions like generalized anxiety disorder and insomnia due to changing lifestyle and increasing stress levels is expected to boost demand for benzodiazepine drugs globally. According to the report published by WHO, around 264 million people suffer from depression and anxiety worldwide. More than 38% of Americans had experience symptoms of anxiety, according to the Anxiety and Depression Association of America. Increasing adoption of benzodiazepines to manage symptoms of mental health issues can drive the global benzodiazepine drugs market growth. However, factors such as concerns regarding side effects associated with long term use of benzodiazepines including drowsiness, dizziness, and impaired coordination and memory can pose a challenge for market players. Moreover, availability of alternative treatments can hamper the market growth over the forecast period. Meanwhile, advancements in drug development to introduce safer variants of benzodiazepines with fewer side effects present significant opportunities for the market growth in the near future.

    Key Features of the Study:

    Detailed Segmentation

    Table of Contents

    1. Research Objectives and Assumptions

    2. Market Purview

    3. Market Dynamics, Regulations, and Trends Analysis

    4. Global Benzodiazepine Drugs Market - Impact of Coronavirus (COVID-19) Pandemic

    5. Global Benzodiazepine Drugs Market, By Product, 2020 - 2032, (USD Mn)

    6. Global Benzodiazepine Drugs Market, By Route of Administration, 2020 - 2032, (USD Mn)

    7. Global Benzodiazepine Drugs Market, By Application, 2020 - 2032, (USD Mn)

    8. Global Benzodiazepine Drugs Market, By Distribution Channel, 2020 - 2032, (USD Mn)

    9. Global Benzodiazepine Drugs Market, By Region, 2020 - 2032, (USD Mn)

    10. Competitive Landscape

    11. Analyst Recommendations

    12. References and Research Methodology

    (ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
    ¨Ï Copyright Global Information, Inc. All rights reserved.
    PC¹öÀü º¸±â